XML 71 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (unaudited) (USD $)
 6 Months Ended 138 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Cash flows used in operating activities:      
Net loss $ (2,270,000) $ (2,553,000) $ (70,264,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain on patent rights assignment     (2,000,000)
Gain on bargain purchase     (25,282,000)
Depreciation and amortization 19,000 24,000 1,799,000
Non-cash interest expense     211,000
Share-based compensation 76,000 168,000 2,664,000
Issuance of warrants for lease termination     377,000
Accretion of liabilities     152,000
Impairment of property and equipment     125,000
Loss on impairment of in-process research and development     6,000,000
Write-off of deferred tax liability     (2,281,000)
Gain on marketable securities available for sale     (263,000)
(Gain) loss from disposal of property and equipment     83,000
Other, net     267,000
Change in operating assets and liabilities (net of amounts acquired):      
Other current assets 15,000 (5,000) 2,835,000
Other assets 40,000 40,000 7,366,000
Accounts payable 322,000 (34,000) (1,803,000)
Accrued expenses and other liabilities 71,000 (257,000) (19,150,000)
Deferred rent (13,000) (16,000) 3,000
Net cash used in operating activities (1,740,000) (2,633,000) (99,161,000)
Cash flows used in investing activities:      
Cash received from Merger     30,392,000
Payment of deferred transaction costs     (1,186,000)
Purchase of property and equipment (17,000) (1,000) (1,896,000)
Proceeds from sale of marketable securities     15,369,000
Proceeds from sale of property and equipment     358,000
Proceeds from patent rights assignment     2,000,000
Net cash used in investing activities (17,000) (1,000) 45,037,000
Cash flows provided by (used in) financing activities:      
Proceeds from issuance of convertible notes payable and related warrants for common stock     10,841,000
Proceeds from issuance of bank note payable     4,000,000
Proceeds from stock subject to repurchase     38,000
Proceeds from the issuance of preferred stock 20,000,000   52,316,000
Payment of offering costs 30,000    
Proceeds from the issuance of common stock 1,741,000   15,850,000
Repayment of principal on bank note payable     (4,000,000)
Repayment of principal on convertible notes payables     (105,000)
Repayment of principal on vendor finance agreement (109,000) (66,000) (389,000)
Net cash provided by (used in) financing activities 19,211,000 (127,000) 74,498,000
Net increase (decrease) in cash and cash equivalents 17,454,000 (2,761,000) 20,374,000
Cash and cash equivalents, beginning of period 2,920,000 5,943,000  
Cash and cash equivalents, end of period 20,374,000 3,182,000 20,374,000
Supplemental cash flow information:      
Interest paid 3,000 2,000 118,000
Supplemental disclosure of noncash investing and financing transactions:      
Accrued interest on notes payable converted to equity     163,000
Warrant issued in connection with credit facility     111,000
Accrued deferred transaction costs     482,000
Vendor finance agreement 65,000 68,000 65,000
Preferred Stock
      
Cash flows provided by (used in) financing activities:      
Payment of offering costs (2,083,000)   (2,329,000)
Common Stock
      
Cash flows provided by (used in) financing activities:      
Payment of offering costs $ (338,000) $ (61,000) $ (1,724,000)